Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection (BiLe -Trial) (BiLe)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04523701 |
Recruitment Status :
Recruiting
First Posted : August 24, 2020
Last Update Posted : October 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Bile Leakage | Drug: "white" test" (= the administration of SMOFlipid retrograde through the cystic duct) | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 210 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Prospective randomized, controlled, observer and patient blinded multicentric (4 centres) superiority trial with 2 parallel study groups |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Masking Description: | Patients, care providers and outcome assessors are blinded, the surgical team is not blinded. |
Primary Purpose: | Prevention |
Official Title: | Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection- A Randomized Controlled Multicentric Superiority Trial- The BiLe-Trial (Bile Leakage Trial) |
Actual Study Start Date : | March 25, 2021 |
Estimated Primary Completion Date : | December 2025 |
Estimated Study Completion Date : | December 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental Intervention (treatment)
Open bile ducts are identified by visual control of the liver resection surface combined with the direct injection in the cystic stump of 20-40ml of SMOFlipid 20% Fresenius Kabi Canada Ltd.; authorization number: 57231 (Swissmedic). SMOFlipid is a white oily emulsion containing soya oil and medium chain triglycerides as main active components, normally used as parenteral nutrition as complement for essential fat acids supplementation. In this study the "white" test (= the administration of SMOFlipid retrograde through the cystic duct) is made by injection of one or two 20cc syringes full of lipidic solution (SMOFlipid 20%) in the cystic stump, directing the flow to the intrahepatic ducts. Residual fat emulsion is washed out from the biliary tract by a low pressure infusion of 20 to 50 ml of saline solution. |
Drug: "white" test" (= the administration of SMOFlipid retrograde through the cystic duct)
"white" test" (= the administration of SMOFlipid retrograde through the cystic duct) |
No Intervention: Control Intervention
Open bile ducts are identified in the control group by visual control of the liver resection surface combined with the use of white gauzes (standard procedure)
|
- rate of postoperative bile leakage [ Time Frame: within 30 days postoperative ]Comparison of the rate of postoperative bile leakage in the control and in the intervention group. This is a binary endpoint defined by the presence or absence of the bile leakage (yes or no). Bile leakage is defined as bilirubin concentration in the drain fluid at least 3 times the serum bilirubin concentration on or after postoperative day 3.
- Severity of the bile leakage (Grade A, B or C according to the definition by Koch et al). [ Time Frame: within 30 days postoperative ]The severity of bile leakage is classified according to its impact on patients´ clinical management. Grade A bile leakage causes no change in patients' clinical management. A Grade B bile leakage requires active therapeutic intervention but is manageable without relaparotomy, whereas in Grade C bile leakage relaparotomy is required.
- In-hospital mortality other than related to the bile leakage [ Time Frame: within 30 days postoperative ]In-hospital mortality other than related to the bile leakage
- In-Hospital morbidity other than related to the bile leakage [ Time Frame: within 30 days postoperative ]In-Hospital morbidity other than related to the bile leakage
- Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no) [ Time Frame: within 30 days postoperative ]Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)
- Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no) [ Time Frame: within 30 days postoperative ]Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)
- Interventional drainage (yes/no) [ Time Frame: within 30 days postoperative ]Interventional drainage (yes/no)
- Re-operation (yes/no) [ Time Frame: within 30 days postoperative ]Re-operation (yes/no)
- Intensive care unit (ICU) stay (in days) [ Time Frame: within 30 days postoperative ]Intensive care unit (ICU) stay (in days)
- Total hospital stay (in days) [ Time Frame: within 30 days postoperative ]Total hospital stay (in days)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who will receive an anatomical resection of two or more liver segments for any reason with simultaneous cholecystectomy in elective Setting
- Patients who will receive an anatomical resection of two or more liver segments for any reason which already had a cholecystectomy if intraoperatively the cystic stump can be identified and opened
- Ability of subject to understand character and individual consequences of the clinical Trial
- Informed consent documented by signature
Exclusion Criteria:
- Previous cholecystectomy if intraoperative it is not possible to identify the cystic stump
- Intraoperative hepatico-jejunostomy
- Hypersensitivity to fish-, egg-, soybean or peanut protein or to any of the active ingredients or excipients
- Immunosuppression, pregnancy
- Emergency liver resection because of traumatic liver rupture
- Enrolment of the investigator, his/her family members, employees and other dependent persons
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04523701
Contact: Giulia Manzini, Dr. med. | +41-62-8389734 | giulia.manzini@ksa.ch |
Switzerland | |
Department of Visceral Surgery, Cantonal Hospital of Aarau | Recruiting |
Aarau, Switzerland, 5001 | |
Contact: Giulia Manzini, Dr. med. 062-8389734 giulia.manzini@ksa.ch | |
Principal Investigator: Giulia Manzini, Dr. med. | |
Clarunis Basel, Universitäres Bauchzentrum Basel | Recruiting |
Basel, Switzerland, 4031 | |
Contact: Otto Kollmar, Prof. Dr. med. +41 61 777 73 20 otto.kollmar@clarunis.ch | |
Principal Investigator: Otto Kollmar, Prof. Dr. med. | |
Ospedale Regionale di Lugano | Recruiting |
Lugano, Switzerland, 6900 | |
Contact: Alessandra Cristaudi, Dr. med. 091 811 7208 alessandra.cristaudi@eoc.ch | |
Principal Investigator: Alessandra Cristaudi, Dr. med. | |
Kantonsspital Luzern | Recruiting |
Luzern, Switzerland, 6004 | |
Contact: Andreas Scheiwiller, Dr. med. 041 2054539 andreas.scheiwiller@luks.ch | |
Principal Investigator: Andreas Scheiwiller, Dr. med. | |
Kantonsspital St. Gallen | Recruiting |
St. Gallen, Switzerland, 9001 | |
Contact: Ignazio Tarantino, PD Dr. med. 071 4941312 Ignazio.tarantino@kssg.ch | |
Principal Investigator: Ignazio Tarantino, PD Dr. med |
Principal Investigator: | Giulia Manzini, Dr. med. | Cantonal Hospital of Aarau, Switzerland |
Responsible Party: | Giulia Manzini, Dr. med., Senior physician, Department of Visceral Surgery, Kantonsspital Aarau |
ClinicalTrials.gov Identifier: | NCT04523701 |
Other Study ID Numbers: |
2020-02081; ex20Manzini |
First Posted: | August 24, 2020 Key Record Dates |
Last Update Posted: | October 12, 2023 |
Last Verified: | October 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Liver resection SMOFlipid 20% White Test |
SMOFlipid Fat Emulsions, Intravenous Parenteral Nutrition Solutions Pharmaceutical Solutions |